nexavar
bayer pharma ag, leverkusen, alemania. - tosilato de sorafenib - comprimido recubierto - 200 mg
nexavar 200 mg comprimido recubierto
bayer s.a. - droguerÍa - sorafenib; - comprimido recubierto - por comprimido - - otros agentes antineoplÁsicos
nexavar®
bayer ag. - sorafenib (eq. a 274 mg de tosilato de sorafenib micronizado o 274 mg de tosilato de sorafenib n micronizado)) - comprimido recubierto - 200 mg
sorafenib swanpond investments 200 mg comprimidos recubiertos con pelicula efg, 112
sorafenib swanpond investments 200 mg comprimidos recubiertos con pelicula efg, 112
sorafenib accord 200 mg comprimidos recubiertos con pelicula efg, 112 comprimidos
nexavar 200 mg comprimidos recubiertos
avpharma, c.a. - sorafenib - comprimidos recubiertos - 200 mg
sepiterab comprimidos recubiertos 200 mg
novartis chile s.a. - sorafenib - sin formulas
nexavar comprimidos recubiertos 200 mg (sorafeni)
bayer s.a. - sorafenib - sin formulas
cabometyx
ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - agentes antineoplásicos - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.